Conclusions and Relevance
muscle-invasive bladder cancer, high-grade disease
RECURRENCE
In this cohort study, gemcitabine and docetaxel therapy was associated with less high-grade disease recurrence and treatment discontinuation than BCG therapy. These findings suggest that, while awaiting results from an ongoing randomized clinical trial during the current BCG shortage, use of gemcitabine and docetaxel can be considered for recommendation in updated practice guidelines.This cohort study compares outcomes of treatment with sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Guérin among patients with high-risk non–muscle-invasive bladder cancer.